Peptor Overview
- Year Founded
-
1993
- Status
-
Acquired/Merged
- Employees
-
53
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$69.7M
Peptor General Information
Description
Developer of products to treat autoimmune diseases. The company develops small cyclical analogues of peptide loop drugs to treat cancer, bacterial and fungal infections, autoimmune diseases, multiple sclerosis and other disorders.
Contact Information
Corporate Office
- Kiryat Weizmann
- Rehovot 78326
- Israel
Corporate Office
- Kiryat Weizmann
- Rehovot 78326
- Israel
Peptor Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 17-May-2004 | $69.7M | Completed | Generating Revenue | ||
| 7. Later Stage VC | 01-Nov-1999 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 29-Sep-1998 | Completed | Startup | |||
| 5. IPO | 25-Jun-1997 | Cancelled | Startup | |||
| 4. Early Stage VC | 01-May-1996 | Completed | Startup | |||
| 3. Early Stage VC | 01-Nov-1995 | Completed | Startup | |||
| 2. Early Stage VC | 01-Dec-1993 | $10M | $11M | Completed | Startup | |
| 1. Seed Round | 01-May-1993 | $1M | $1M | Completed | Startup |
Peptor Patents
Peptor Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2005072056-A2 | Hsp therapy in conjunction with a low antigenicity diet | Inactive | 28-Jan-2004 | ||
| WO-2005072056-A3 | Hsp therapy in conjunction with a low antigenicity diet | Inactive | 28-Jan-2004 | ||
| WO-2004110337-A2 | Cell permeable conjugates of peptides for inhibition of protein kinases | Inactive | 12-Jun-2003 | ||
| WO-2004110337-A3 | Cell permeable conjugates of peptides for inhibition of protein kinases | Inactive | 12-Jun-2003 | ||
| WO-2004098489-A2 | Compositions and methods for modulation of specific epitopes of hsp60 | Inactive | 12-May-2003 | A61K38/1709 |
Peptor Signals
Peptor Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ampal | Venture Capital | Minority | ||
| Carlyle AlpInvest | PE/Buyout | Minority | ||
| Citibank | Corporation | Minority | ||
| Clal Biotechnology Industries | Venture Capital | Minority | ||
| David Blech & Co | Other | Minority |
Peptor FAQs
-
When was Peptor founded?
Peptor was founded in 1993.
-
Where is Peptor headquartered?
Peptor is headquartered in Rehovot, Israel.
-
What is the size of Peptor?
Peptor has 53 total employees.
-
What industry is Peptor in?
Peptor’s primary industry is Biotechnology.
-
Is Peptor a private or public company?
Peptor is a Private company.
-
What is the current valuation of Peptor?
The current valuation of Peptor is .
-
What is Peptor’s current revenue?
The current revenue for Peptor is .
-
How much funding has Peptor raised over time?
Peptor has raised $63.5M.
-
Who are Peptor’s investors?
Ampal, Carlyle AlpInvest, Citibank, Clal Biotechnology Industries, and David Blech & Co are 5 of 11 investors who have invested in Peptor.
-
When was Peptor acquired?
Peptor was acquired on 17-May-2004.
-
Who acquired Peptor?
Peptor was acquired by Evotec International.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process